




Figure S1: The Na+ dependence of phosphorylation from figure 2C shown in separate 
panels for the three mutants with statistics. Error bars indicate SEM for the independent 
experimental points (n = 4-5). The indicated Hill coefficients (nH) and K0.5 values with SEM 
values were obtained by fitting the Hill equation 1 to the data, resulting in the lines shown. 
The 3.5-fold loss of affinity (reduced K0.5) for p.Leu302Arg (p.L302R) is significant (p<0.001 
using one-way ANOVA test). The obtained Hill coefficients indicate WT-like cooperativity of 
Na+ binding for p.Leu302Arg (p.L302R), whereas cooperativity was lost for p.Gly303Arg 
(p.G303R) and p.Met859Arg (p.M859R), as also indicated by the crossing of the line 











Figure S2:  Dephosphorylation of the Na/K-ATPase phosphoenzyme upon addition of ADP 
for the determination of the distribution of Na+-bound E1P and the K+-sensitive E2P form: 
The amplitude of the rapid phase of dephosphorylation was either WT-like (p.Gly303Arg 
(p.G303R) and p.Met859Arg (p.M859R)) or reduced in size (p.Leu302Arg (p.L302R)) 
indicating the presence of more E2P than seen for the WT. These data (n = 13-26) indicate 
that the reduced K+ sensitivity observed for all mutants (see figure 2D), is due to a direct 
effect on K+ interaction with the E2P state and not caused indirectly by a shift of the E1P-E2P 













Figure S3: Influence of extracellular pH changes on intracellular pH in adrenal NCI-H295R 
cells expressing wildtype (WT) or different mutant (p.Leu302Arg (p.L302R), p.Gly303Arg 
(p.G303R), p.Met859Arg (p.M859R)) ouabain-insensitive rat Atp1a1. Cells were analysed 2 
days after transient transfection with Atp1a1 containing bicistronic plasmids using 
electroporation. Transfected cells were identified using anti-CD8 coated dynabeads and 
compared to untransfected cells (devoid of beads) from the same dish. The pH of the 
extracellular solution was changed from control pH 7.4 to pH 7.0, followed by pH 8.0. The 
intracellular pH was measured using the pH-sensitive BCECF dye. BCECF ratios (495/440 nm), 
normalized to the baseline pH of untransfected cells, are show in (A) indicating intracellular 
acidification by a decreased ratio and alkalinization by an increased ratio, respectively. 
Expression of the p.Leu302Arg mutant (n=10) led to stronger changes of the intracellular pH 
upon altering the extracellular pH, whereas p.Gly303Arg (n=7) and p.Met859Arg (n=7) 
mutant cells were not different from WT cells (n=8). (B) Reactivity of the intracellular pH to 
alterations of the extracellular pH was quantified by calculating the initial changes in the 






















slope at the end of the pH7.4 control). *p<0.05 compared to WT at pH 8.0; n is equal to the 
number of dishes (measured from different cell passages and at different days of 
experiments). 
  
SUPPLEMENTAL METHODS AND RESULTS: 
PATIENTS 
Table S1: 
Individual A-II-1 B-II-1 C-II-2 
    






Gender female female male 
    
Age at manifestation 6 months 2 months 6 days 
First symptom generalized seizures generalized 
seizures 
generalized seizures 
    
Initial laboratory findings:    
S-Na (mmol/L) (136-144) 135 139 141 
S-K (mmol/L) (3.6-5.2) 3.8 4.2 2.1 
S-Ca (mmol/L) (2.1-2.6) 2.24 2.58 0.9 (ionized, 1.05-
1.35) 
S-Mg (mmol/L) (0.75-1.1) 0.36 0.35 0.30 
S-HCO3 (mmol/L) (22-26) 26.7 22.0 27.0 
    
Ca/Crea-ratio (mol/mol) 
(<2.2) 
0.24 0.46 4.95 
FE-Mg (%) (3-5%) 26.0 33.8 nd 
    
    
Age at last follow-up 4 years 10 years 6 years 
    
Actual laboratory findings:    
S-Na (mmol/L) (136-144) 136 140 139 
S-K (mmol/L) (3.6-5.2) 3.3 3.0 3.9 
S-Ca (mmol/L) (2.1-2.6) 2.52 2.23 2.13 
S-Mg (mmol/L) (0.75.-1.1) 0.57 0.28 0.62 
    
S-HCO3 (mmol/L) (22-26) 26.3 25.0 22.0 
Ca/Crea-ratio (mol/mol) 
(<0.9) 
0.41 0.40 0.44 
FE-Mg (%) (3-5%) 15.3 27.0 21.3 
    
nephrocalcinosis no no no 
    
arterial hypertension no no No 
cardiac examinationa normal n.d. normal 
    
renin (ng/L) (5-67) 53ng/L  n.d. n.d. 
PRAb (ng/mL/h) (<7) n.d. 15.5 1.33 
aldosterone (ng/dL) (1-40) 5.2 11.2 1.8 
ADRRc/ARRd (<30) 1.0 (ADRR) 0.7 (ARR) 1.4 (ARR) 
    
seizure activity repeated status 
epilepticus 
monthly seizures frequent seizures, 
repeated status 
epilepticus  
cerebral imaging (MRI) initially normal,  

















delay, speech delay, 
diagnosis of severe 
autism, self-biting 
behaviour 
    
ATP1A1 mutations    
- nucleotide level c.905T>C        c.907G>C       c.2576T>G     
- protein level p.Leu302Arg p.Gly303Arg p.Met859Arg 
a by electrocardiogram and echocardiography, b PRA = plasma renin activity, c ADRR = aldosterone-direct renin-
ratio, d ARR = aldosterone-renin activity-ratio, 
 




The family C trio as well as individual A-II-1 were subjected to whole exome sequencing in 
separate studies.  
Family C was enrolled within the TIDEX gene discovery project (H12-00067), which was 
approved by the Research Ethics Board of BC Children’s and Women’s Hospital, University of 
British Columbia, Vancouver, Canada. Whole exome sequencing was performed for the 
affected child (C-II-2), mother (C-I-2), and father (C-I-1) of family C. C-II-2 was sequenced 
using the Agilent SureSelectXT kit and Illumina HiSeq 4000 (Macrogen, South Korea). Mother 
and father were sequenced using the Agilent V4 51Mb kit and Illumina HiSeq 2000 (Perkin-
Elmer, CA, USA). The sequence data was processed and analyzed using a semi-automated 
pipeline as previously reported 2. Sequencing reads were aligned to the hg19 human 
reference genome. Rare variants were assessed for predicted functional impact, using CADD, 
SIFT and PolyPhen, and were screened under multiple inheritance models. For patient C-II-2, 
homozygous variants in 9 genes, compound-heterozygous variants in 6 genes, hemizygous 
variants in 3 genes, and de-novo variant in 1 gene were identified.  
Singleton exome sequencing of individual A-II-1 was performed from 200ng of genomic DNA. 
Target enrichment was carried out using the standard protocol SureSelectXT Automated 
Target Enrichment for Illumina paired-end multiplexed sequencing, and the Agilent Bravo 
automated liquid handling platform 3. After validation (2200 TapeStation; Agilent 
Technologies, CA, USA) and quantification (Qubit System; Invitrogen, Waltham, MA, USA), 
2 x 75 bp paired-end reads were sequenced on a HiSeq 4000 (Illumina, San Diego, California). 
For data analysis, the VARBANK pipeline v.2.15 (unpublished) and the corresponding filter 
interface was used. Sequence reads were mapped to the hg19/GRCh37 human reference 
genome using the Burrows Wheeler Aligner (BWA) alignment algorithm with a mean target 
coverage of 80 reads per base and 82.4% of targeted bases covered more than 30x. 
In individual A-II-1, 4 genes with homozygous variants and 4 genes with more than one 
potentially pathogenic variant were identified. In addition, the data analysis of individual A-
II-1 revealed heterozygous variants in 310 genes.  
Comparison of exome data from the two affected individuals (A-II-1 and C-II-2) 
demonstrated no additional shared gene, beyond ATP1A1, with homozygous, compound-
heterozygous, or de-novo mode of inheritance. Finally, we also could not identify a gene 
with a rare heterozygous variant shared by both individuals (A-II-1 and C-II-2).  
In contrast, both individuals were found to carry a single heterozygous mutation, 
p.Leu302Arg and p.Met859Arg in ATP1A1, respectively. Targeted Sanger sequencing of 
index, mother, father and unaffected sibs for family A and C confirmed that both variants 
occurred de-novo. Subsequently, conventional Sanger sequencing of the entire coding region 
and adjacent exon/intron boundaries of ATP1A1 revealed a third heterozygous mutation, 
















































(RefSeq NM_000701, NP_000692, Transcript ID ENST00000295598, UniProt P05023) 
 
Table S2: Mutations in ATP1A1. In silico analyses predicted the variants to be pathogenic 
(p.Leu302Arg: CADD4 (32.0); SIFT5 (Damaging; 0.000); Polyphen26 (Probably damaging; 
0.985); p.Gly303Arg: CADD (31.0); SIFT (Damaging; 0.000); Polyphen2 (Probably damaging; 
1.000); p.Met859Arg: CADD (24.6); SIFT (Damaging; 0.013); PolyPhen2 (Possibly damaging; 
0.561)), affecting highly conserved amino acid residues of the Na/K-ATPase D1 protein. None 
of the identified mutations are listed in publically available exome or genome databases, i.e. 






MEASUREMENT OF Na/K-ATPase ACTIVITY 
For biochemical studies, mutations were introduced into full-length cDNA encoding the 
ouabain insensitive rat D1-isoform of Na/K-ATPase. COS-1 cells were used to express the 
mutants and wild type, either by the ouabain selection method 7, attempting to obtain 
stable viable cell lines, or by transient expression in the presence of siRNA to knock down 
endogenous Na/K-ATPase 8. Leaky plasma membranes were assayed functionally by 
previously described methods 1. Phosphorylation was carried out for 10 s at 0qC with 2 µM   
[J-32P]ATP in the presence of varying concentrations of NaCl (100 mM for maximum 
phosphorylation), 3 mM MgCl, 20 mM Tris (pH 7.5), 100 PM ouabain, and 20 Pg 
oligomycin/ml, or in the presence of 50 mM NaCl, 3 mM MgCl, 20 mM Tris (pH 7.5), 100 PM 
ouabain, and varying concentrations of KCl with choline chloride added to maintain a 
constant ionic strength.  
For determination of the E1P-E2P-distribution the phosphorylation was carried out in the 
absence of KCl and dephosphorylation was followed by quenching at various time intervals 
after addition of 2.5 mM ADP with 1 mM unlabeled ATP. In all phosphorylation experiments 
the radioactively labeled Na/K-ATPase was separated by acid SDS gel electrophoresis 




Plasmids containing full-length cDNA sequences encoding wild-type or mutant ouabain-
insensitive rat Atp1a1 were generated as described 8, 9. Adrenocortical carcinoma NCI-H295R 
cells (CLS) were transfected using electroporation as described 9. Cells were analyzed 48 
hours after transfection. For patch-clamp, pH, and Ca2+ measurements, transfected cells 
were identified using anti-CD8-coated dynabeads (Life Technologies GmbH).  
Whole-cell patch recordings were performed at room temperature using an EPC 10 amplifier 
(Heka), relative cytosolic pH levels were measured using the ratiometric fluorescent pH 
sensitive dye BCECF-AM (Life Technologies GmbH) as described 9. For Na+-free extracellular 
conditions, bath Na+ was replaced by N-methyl-D-glucamine (NMDG+). In addition, flame 
photometry was used for the determination of intracellular Na+ and K+ contents as described 
10. Intracellular Na+ and K+ contents were measured under control conditions and after 
treatment with 10 µM ouabain inhibiting endogenous human ATP1A1 but not the 
transfected ouabain-insensitive rat ATP1A1. Cultured cells were washed with a Na+-free 
solution before swelling and disruption of cells was induced by incubation in MilliQ-water on 
ice for 1.5 hours. Cell lysates are homogenized mechanically and cleared from cellular debris 
by centrifugation. Finally, Na+- and K+ concentrations in the supernatant were measured 
using flame photometry (PFP7 Industrial Flame Photometer, Jenway/Cole Parmer, 
Staffordshire, UK). Ion concentrations were calculated as ratios of Na+- or K+ content, 
respectively, compared to the sum of Na+ and K+ content. 
 
STATISTICAL ANALYSIS 
Phosphorylation data were analyzed using the SigmaPlot program (SPSS, Inc.) for non-linear 
regression using the Hill equation for cooperative binding 1. Statistical significance was 
tested using Student’s t test (for paired or unpaired samples as appropriate). All data are 
presented as mean ± SEM. For multiple comparisons, an ANOVA plus Bonferroni or Holm-
Sidak post-hoc test was used. Differences between groups were considered significant if 
p˂0.05 for single comparisons or p<0.01 for multiple comparisons. 
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